(MCRB) Seres Therapeutics - Performance -26.9% in 12m
MCRB performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-88.16%
#167 in Peer-Group
Rel. Strength
17.85%
#6305 in Stock-Universe
Total Return 12m
-26.91%
#92 in Peer-Group
Total Return 5y
-88.34%
#109 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | 5.78 |
| High / Low | USD |
|---|---|
| 52 Week High | 29.60 USD |
| 52 Week Low | 6.77 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 95.83 |
| Buy/Sell Signal +-5 | 1.45 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: MCRB (-26.9%) vs XBI (-7%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
3.23% | 73% | 77.8% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-9.1% | -6.38% | 147% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
3.91% | -0.97% | 36% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
1.34% | 27.6% | -4.82% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
3.69% | -7.17% | 1.14% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
18.3% | 43% | -4.19% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-4.03% | 58.7% | -9.25% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
6.2% | 28.7% | 15.2% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: MCRB vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for MCRB
| Total Return (including Dividends) | MCRB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 66.48% | 3.36% | 5.25% |
| 3 Months | -7.27% | 15.73% | 24.13% |
| 12 Months | -26.91% | -7.02% | 14.15% |
| 5 Years | -88.34% | -24.21% | 111.83% |
| Trend Score (consistency of price movement) | MCRB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 72.6% | 4.4% | 81% |
| 3 Months | -29.5% | 78.8% | 96.9% |
| 12 Months | -82.7% | -85.8% | 44.9% |
| 5 Years | -91.6% | -52.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th97.50 | 61.08% | 58.18% |
| 3 Month | %th20.50 | -19.87% | -25.29% |
| 12 Month | %th54.50 | -21.39% | -35.97% |
| 5 Years | %th46.00 | -84.62% | -94.50% |
FAQs
Does Seres Therapeutics (MCRB) outperform the market?
No,
over the last 12 months MCRB made -26.91%, while its related Sector, the SPDR S&P Biotech (XBI) made -7.02%.
Over the last 3 months MCRB made -7.27%, while XBI made 15.73%.
Performance Comparison MCRB vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
MCRB vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 28.7% | 61.2% | -40.2% | -41% |
| US NASDAQ 100 | QQQ | 29% | 61.2% | -40.9% | -40% |
| German DAX 40 | DAX | 30.9% | 67.9% | -52.4% | -56% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 28.9% | 63.2% | -43.6% | -47% |
| Hongkong Hang Seng | HSI | 29.1% | 60.4% | -59.7% | -65% |
| India NIFTY 50 | INDA | 30.6% | 63% | -40.5% | -26% |
| Brasil Bovespa | EWZ | 26.3% | 57.7% | -65.3% | -37% |
MCRB vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 30.1% | 60.6% | -44.3% | -51% |
| Consumer Discretionary | XLY | 29.2% | 63.3% | -32.6% | -45% |
| Consumer Staples | XLP | 28.4% | 65.8% | -41.9% | -36% |
| Energy | XLE | 28.4% | 59.4% | -36.1% | -27% |
| Financial | XLF | 28% | 61.4% | -45.1% | -57% |
| Health Care | XLV | 29.3% | 64.3% | -32.9% | -22% |
| Industrial | XLI | 28.7% | 62.3% | -48.1% | -52% |
| Materials | XLB | 26.5% | 62.2% | -44.7% | -33% |
| Real Estate | XLRE | 28.8% | 65.5% | -39.9% | -40% |
| Technology | XLK | 28% | 57.8% | -42.5% | -38% |
| Utilities | XLU | 29.8% | 64.7% | -43.4% | -50% |
| Aerospace & Defense | XAR | 30.9% | 59.4% | -58.8% | -76% |
| Biotech | XBI | 27.8% | 63.1% | -27% | -20% |
| Homebuilder | XHB | 26.2% | 59.5% | -33% | -32% |
| Retail | XRT | 26.2% | 61.5% | -35.9% | -38% |
MCRB vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 27.8% | 58.0% | -31.8% | -19% |
| Natural Gas | UNG | 38.2% | 76.3% | -23.4% | -25% |
| Gold | GLD | 28.5% | 67.7% | -60.8% | -66% |
| Silver | SLV | 27.7% | 59.6% | -57.6% | -45% |
| Copper | CPER | 29.7% | 61.9% | -57.3% | -38% |
MCRB vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 30.6% | 65.4% | -36.8% | -25% |
| iShares High Yield Corp. Bond | HYG | 29.9% | 64.9% | -39.1% | -37% |